Solid pharmaceutical composition containing 1,3,5-triazine derivative or salt thereof

Patent metadata

Field	Value
Publication number	US-12097204-B2
Application number	US-201917272915-A
Country	US
Kind code	B2
Filing date	Sep 3, 2019
Priority date	Sep 3, 2018
Publication date	Sep 24, 2024
Grant date	Sep 24, 2024

Abstract

A solid pharmaceutical composition containing a 1,3,5-triazine derivative or a pharmaceutically acceptable salt thereof and a preparation method therefor. In particular, involved are a solid pharmaceutical composition containing 4-(tert-butoxyamino)-6-(6-(trifluoromethyl)pyridin-2-yl)-N-(2-(trifluoromethyl)pyridin-4-yl)-1,3,5-triazine-2-amine or a pharmaceutically acceptable salt thereof and a preparation method therefor. The solid pharmaceutical composition has a good stability, a fast dissolution rate and a high bioavailability, and is suitable for clinical production and use.

First claim

The invention claimed is:

1. A solid pharmaceutical composition, comprising a mixture comprising monomethanesulfonate of the compound of formula I, and a fluidization excipient, wherein the mixture comprising the monomethanesulfonate of the compound of formula I further comprises a binder, a solubilizer and a diluent;

wherein the solid pharmaceutical composition comprises 10-100 mg of the monomethanesulfonate of the compound of formula I; or alternatively, the monomethanesulfonate of the compound of formula I is present in an amount of 0.5-50 wt %, based on the total mass of the solid pharmaceutical composition;
wherein the binder is selected from hydroxypropyl methylcellulose, hydroxypropyl cellulose and povidone; the solubilizer is selected from sodium dodecyl sulfate and magnesium dodecyl sulfate; and the diluent is mannitol.

2. The solid pharmaceutical composition according to claim 1 , wherein a binder is present in an amount of 1-10 wt %, based on the solid pharmaceutical composition; or, the solubilizer is present in an amount of 0.5-5 wt % based on the solid pharmaceutical composition; or a diluent in the solid pharmaceutical composition is present in an amount of 10-90 wt %, based on the solid pharmaceutical composition.

3. The solid pharmaceutical composition according to claim 1 further comprising an additional excipient.

4. The solid pharmaceutical composition according to claim 1 , wherein the diluent in the mixture comprising the monomethanesulfonate of the compound of formula I is present in an amount of 10-50 wt %, based on the total amount of diluents in the solid pharmaceutical composition; or, the diluent in the mixture comprising the monomethanesulfonate of the compound of formula I is present in an amount of 1-45 wt %, based on the total mass of the solid pharmaceutical composition; or, the mass ratio of the monomethanesulfonate of the compound of formula I to the diluent in the mixture is 1:0.5 to 1:10.

5. The solid pharmaceutical composition according to claim 1 , wherein the fluidization excipient comprises a diluent and a disintegrant.

6. The solid pharmaceutical composition according to claim 3 , wherein the additional excipient comprises a lubricant.

7. The solid pharmaceutical composition according to claim 1 , wherein the solid pharmaceutical composition is prepared by fluidized bed granulation.

8. A method for preparing the solid pharmaceutical composition according to claim 1 , wherein the method is fluidized bed granulation, comprising: (1) preparing a suspension comprising the monomethanesulfonate of the compound of formula I, the suspension further comprises a binder selected from hydroxypropyl methylcellulose, hydroxypropyl cellulose and povidone, a solubilizer selected from sodium dodecyl sulfate and magnesium dodecyl sulfate, and a diluent is mannitol; (2) preparing a fluidization excipient; (3) placing the fluidization excipient into a fluidized bed, and spraying the suspension comprising the monomethanesulfonate of the compound of formula I into the fluidized bed for granulation; (4) sizing; and optionally (5) mixing an additional excipient with the sized materials.

9. The method according to claim 8 , wherein, in step (1), a solvent of the suspension is selected from methanol, ethanol, isopropanol, acetone, water, and any combination thereof; and the mass ratio of the monomethanesulfonate of the compound of formula I to the solvent in the suspension is 1:(5-20).

10. The method according to claim 8 , wherein in step (1), the monomethanesulfonate of the compound of formula I is first mixed with the binder, the diluent and/or the solubilizer to give a mixture comprising the monomethanesulfonate of the compound of formula I, and then the mixture is mixed with the solvent to give the suspension comprising the monomethanesulfonate of the compound of formula I; or, after step (3), the granulation process in the fluidized bed further comprises drying to remove the solvent from the suspension.

11. The solid pharmaceutical composition according to claim 1 , wherein the binder in the mixture comprising the monomethanesulfonate of the compound of formula I is selected from hydroxypropyl methylcellulose and hydroxypropyl cellulose.

12. The solid pharmaceutical composition according to claim 2 , wherein the solubilizer in the mixture comprising the monomethanesulfonate of the compound of formula I is sodium dodecyl sulfate.

13. The solid pharmaceutical composition according to claim 5 , wherein the diluent in the fluidization excipient is selected from microcrystalline cellulose, lactose, starch, mannitol, xylitol, a mixture of microcrystalline cellulose and lactose, a mixture of microcrystalline cellulose and starch, a mixture of microcrystalline cellulose and mannitol, and a mixture of microcrystalline cellulose and xylitol; and the disintegrant in the fluidization excipient is selected from croscarmellose sodium, sodium carboxymethyl starch, crospovidone and low substituted hydroxypropyl cellulose, and the disintegrant is present in an amount of 1-10 wt %, based on the solid pharmaceutical composition.

14. The solid pharmaceutical composition according to claim 6 , wherein the lubricant is selected from magnesium stearate, glyceryl behenate, sodium lauryl sulfate, and sodium stearyl fumarate, and the lubricant is present in an amount of 0.5-5 wt %, based on the solid pharmaceutical composition.

15. The solid pharmaceutical composition according to claim 1 , wherein the solid pharmaceutical composition is a tablet, pill, capsule, powder, or granule.

16. The method according claim 8 , comprising (1) preparing the suspension comprising the monomethanesulfonate of the compound of formula I, the binder, the solubilizer and the diluent; (2) mixing a diluent with a disintegrant to give the fluidization excipient; (3) placing the fluidization excipient of step (2) into a fluidized bed reactor, and spraying the suspension of step (1) into the fluidized bed for granulation; (4) sizing; and optionally (5) mixing a lubricant with a sized material from step (4).

17. The method according claim 16 , wherein, in step (3), an air input in the fluidized bed reactor is 200-1000 m 3 /h; an air input temperature in the fluidized bed reactor is 40-80° C.; and the suspension is sprayed into the fluidized bed at an atomization pressure of 1-5 bar.

Assignees

• Chia Tai Tianqing Pharmaceutical Group Co Ltd
• Lianyungang Runzhong Pharmaceutical Co Ltd
• Centaurus Biopharma Co Ltd

Inventors

• Sun Yuanyuan
• Zhou Shan
• Liu Lei
• Dong Ping
• Gao Jing
• Li Laicun
• Chen Zhilin
• Xu Yi
• Wang Shang

Classifications

• A61K47/14

  Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters · CPC title

• A61K9/2095

  Tabletting processes · CPC title

• A61K31/53 Primary

  having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine (melarsoprol A61K31/555 {; with four nitrogen atoms A61K31/495}) · CPC title

• A61K9/2054

  Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose · CPC title

• A61P35/00

  Antineoplastic agents · CPC title